[{"orgOrder":0,"company":"Albumedix","sponsor":"Valneva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Expanded Collaboration","leadProduct":"Aluminium Hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Albumedix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Albumedix \/ Valneva","highestDevelopmentStatusID":"12","companyTruncated":"Albumedix \/ Valneva"}]

Find Clinical Drug Pipeline Developments & Deals by Sartorius Stedim Biotech

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Albumedix Recombumin® rHA is an essential component in VLA2001, used in the manufacturing process and final formulation of the vaccine. VLA2001 is produced on Valneva’s established Vero-cell platform, leveraging the manufacturing technology.

                          Brand Name : VLA2001

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          April 14, 2022

                          Lead Product(s) : VLA2001,CPG ODN 1018,Aluminium Hydroxide

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Valneva

                          Deal Size : Undisclosed

                          Deal Type : Expanded Collaboration

                          blank